X0206 3 2021-02-15 0 0001270073 INTERCEPT PHARMACEUTICALS, INC. ICPT 0001846325 DeFrancesco Lisa C/O INTERCEPT PHARMACEUTICALS, INC. 10 HUDSON YARDS, FLOOR 37 NEW YORK NY 10001 0 1 0 0 SVP, IR & Corp. Affairs Common Stock 11592 D Option to Purchase Common Stock 65.87 2029-10-01 Common Stock 3825 D Option to Purchase Common Stock 99.66 2030-01-23 Common Stock 2600 D Option to Purchase Common Stock 29.46 2031-01-22 Common Stock 7600 D Includes both restricted stock units that represent a contingent right to receive one share of the Issuer's Common Stock, as well as shares of Common Stock. The award is subject to a four-year vesting period, with 25% of the shares subject to the award vesting and becoming exercisable in an initial installment on the anniversary of the Vesting Commencement Date and 1/48th of the shares subject to the award vesting and becoming exercisable each month thereafter. The Vesting Commencement Date is October 1, 2019. The award is subject to a four-year vesting period, with 25% of the shares subject to the award vesting and becoming exercisable in an initial installment on the anniversary of the Vesting Commencement Date and 1/48th of the shares subject to the award vesting and becoming exercisable each month thereafter. The Vesting Commencement Date is January 1, 2020. The award is subject to a four-year vesting period, with 25% of the shares subject to the award vesting and becoming exercisable in an initial installment on the anniversary of the Vesting Commencement Date and 1/48th of the shares subject to the award vesting and becoming exercisable each month thereafter. The Vesting Commencement Date is January 1, 2021. Exhibit List- Exhibit 24.1- Power of Attorney /s/ Sandip Kapadia, as attorney-in-fact 2021-02-17